Mirum Pharmaceuticals, Inc. 10-Q Summary
Business Context and Reporting Period
Mirum Pharmaceuticals is a clinical-stage biopharmaceutical company developing maralixibat and volixibat for rare cholestatic liver diseases. The filing covers the quarter ended March 31, 2020 and was filed May 7, 2020. The company had no approved products and had never generated product revenue.
- Maralixibat was being developed for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and other indications.
- Volixibat was being developed for adult cholestatic liver diseases.
- The company had 41 full-time employees as of March 31, 2020.
Financial Performance and Position
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue in either period |
| Research and development expense | $17.3 million | $4.9 million | +$12.5 million |
| General and administrative expense | $4.7 million | $1.3 million | +$3.4 million |
| Total operating expenses | $22.0 million | $6.2 million | +$15.8 million |
| Net loss | $21.3 million | $6.0 million | +$15.4 million loss |
| Basic and diluted net loss per share | $0.86 | $2.37 | Lower loss per share due primarily to increased share count |
| Net cash used in operating activities | $18.4 million | $2.4 million | +$15.9 million use |
- Cash and cash equivalents were $72.0 million at March 31, 2020, compared with $12.0 million at December 31, 2019.
- Short- and long-term investments totaled $94.0 million, resulting in cash, cash equivalents and investments of $166.1 million.
- Accumulated deficit was $91.2 million; total stockholders’ equity was $156.1 million.
- Total liabilities were $16.7 million, consisting primarily of accounts payable, accrued expenses, and operating lease liabilities. The filing does not report outstanding debt financing.
- Net cash increased $60.1 million during the quarter, principally from $44.7 million of follow-on offering proceeds and $33.8 million of investment maturities and paydowns, partly offset by operating cash use.
- Stock-based compensation expense was $2.6 million, compared with $0.2 million in the prior-year quarter.
- Operating loss and net loss were the same in substance because the company had no revenue and only modest interest and other income; a gross or operating margin percentage is not meaningful.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased primarily because of manufacturing activities supporting clinical supplies and NDA registration, PFIC and ALGS clinical trials, increased personnel costs, consulting, and non-clinical activities.
- General and administrative expense rose with headcount growth, stock-based compensation, public-company insurance and compliance costs, professional services, and commercial preparation activities.
- The company completed a January 13, 2020 follow-on offering of 2.4 million shares at $20.00 per share, generating net proceeds of $44.7 million.
- Weighted-average shares outstanding increased to 24.7 million from 2.5 million in Q1 2019, reflecting the IPO, follow-on offering, and related equity issuances.
- Interest income increased to $0.7 million from $0.2 million due to larger cash and investment balances.
- Shire transition services were completed in 2019; no Shire service or pass-through expenses were recorded in Q1 2020.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management planned to begin a rolling FDA NDA submission for maralixibat in ALGS in the third quarter of 2020, complete the submission in the first quarter of 2021, and potentially launch in the second half of 2021, subject to regulatory and clinical requirements.
- The company withdrew guidance regarding initiation and enrollment of maralixibat and volixibat studies because COVID-19 affected clinical-trial enrollment and conduct, including the Phase 3 MARCH trial.
- Management stated that COVID-19 had not materially affected first-quarter financial statements and did not then expect it to change the projected ALGS NDA timing, but acknowledged substantial uncertainty involving enrollment, trial operations, suppliers, regulators, employees, financing, and business continuity.
- The company expects substantial additional operating losses as it advances clinical programs, prepares for commercialization, expands its workforce, seeks regulatory approval, and incurs public-company costs.
- Management believed available cash, cash equivalents, and investments were sufficient to fund operations for at least twelve months from the financial statement issuance date.
- Future funding may be required through equity, debt, collaborations, or licensing transactions. Additional equity financing could dilute existing holders, while debt or strategic transactions could impose restrictions or require surrendering valuable rights.
- License obligations include potential development, regulatory, and commercial milestone payments and tiered royalties to Shire and other licensors. As of March 31, 2020, no additional milestones were accrued because future payments were not considered probable.
- Operating lease liabilities totaled approximately $3.6 million, with undiscounted future lease payments of $4.4 million.
- The company reported no material pending legal proceedings and no off-balance-sheet arrangements.
- Key business risks include clinical-trial failure or delay, regulatory non-approval, COVID-19 disruption, limited patient populations, manufacturing dependence, third-party CRO reliance, intellectual-property challenges, competition, reimbursement uncertainty, and the need for additional capital.
Investor Verification Priorities
- Verify subsequent progress, delays, or changes to the ALGS NDA submission and potential launch timeline.
- Monitor enrollment, data quality, and timing for the Phase 3 MARCH PFIC trial and other COVID-19-affected studies.
- Reconcile cash burn with the stated liquidity runway and assess the timing and terms of any future financing.
- Review clinical, regulatory, and manufacturing milestones that could trigger contingent payments under the Shire, Satiogen, Pfizer, and Sanofi agreements.
- Assess dilution from the 4.4 million outstanding stock options, additional reserved shares, and future equity offerings.
- Evaluate safety signals, including liver-enzyme elevations and gastrointestinal adverse events, and their potential effect on regulatory approval and labeling.